Navigation Links
Endo International plc Announces Proposed Private Offering of Senior Secured Notes
Date:4/10/2017

DUBLIN, April 10, 2017 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that Endo Designated Activity Company, Endo Finance LLC and Endo Finco Inc. (collectively, the "Issuers"), its wholly-owned subsidiaries, intend to offer senior secured notes, subject to market and customary conditions. The notes will be senior obligations of the Issuers and will be guaranteed by Endo and certain of Endo's subsidiaries and will be secured by first priority liens on the same collateral that secures Endo's obligations under its previously announced newly proposed senior secured credit facilities.

Endo intends to use the net proceeds from the proposed offering, together with the proceeds of its new term loan facility and cash on hand, to repay all its outstanding loans and all other obligations under its existing credit facilities (the "Refinancing") and to pay related fees and expenses.

The notes and the related guarantees have not been and will not be registered under the Securities Act of 1933 (the "Securities Act"), as amended, or any applicable state or foreign securities laws, and will be offered only to qualified institutional buyers in reliance on Rule 144A, and to persons outside the United States in compliance with Regulation S under the Securities Act. Unless so registered, the notes and the related guarantees may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. This press release will not constitute an offer to sell or a solicitation of an offer to buy any notes or any other securities.

About Endo International plc

Endo International plc (NASDAQ: ENDP) is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, Endo's financing plans, including Endo's intention to offer notes, the Refinancing and the details thereof and the use of proceeds of the proposed offering.  Endo has tried, whenever possible, to identify such statements by words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "projected," "forecast," "will," "may" or similar expressions. Endo has based these forward-looking statements on its current expectations and projections about the growth of its business, its financial performance and the development of its industry.  Because these statements reflect Endo's current views concerning future events, these forward-looking statements involve risks and uncertainties. There can be no assurance that Endo will be able to complete the proposed offering on the anticipated terms, or at all. Although Endo believes that these forward-looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward looking statements or information in this press release. Investors should note that many factors, as more fully described in the documents filed by Endo with securities regulators in the United States and Canada including under the caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings, as applicable, with the Securities and Exchange Commission and with securities regulators in Canada on the System for Electronic Document Analysis and Retrieval ("SEDAR") and as otherwise enumerated herein or therein, could affect Endo's future financial results and could cause Endo's actual results to differ materially from those expressed in forward-looking statements contained in Endo's Annual Report on Form 10-K filed for the year ended December 31, 2016. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities law.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/endo-international-plc-announces-proposed-private-offering-of-senior-secured-notes-300437300.html


'/>"/>
SOURCE Endo International plc
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. International Isotopes Inc. Announces 2016 Year End Financial Results
2. Ampoules Market International Growth, Trends Analysis Report 2022 - ReportsnReports
3. IPI-549 Featured at 15th International Congress on Targeted Anticancer Therapies
4. Endo International plc To Delist Ordinary Shares From The Toronto Stock Exchange
5. Concordia International Corp. Comments on CMA Statement of Objections Related to Hydrocortisone 10mg
6. International Biophysics Announces 34% Revenue Growth for 2016 as it Celebrates 25 Years in the Medical Device Industry.
7. International Isotopes Inc. Announces The Successful Private Placement Of Its Preferred Series C Stock
8. Benitec Biopharma to present expanded data set from pivotal data in hepatitis B virus (HBV) in vivo model at International Liver Meeting in Shanghai, China
9. PharmaForce International: U.S. HEOR Personnel Deployed In a Field Capacity Increased by More Than 50%
10. Concordia International Corp. Makes Final Earn Out Payment to Cinven
11. Die internationale humanitäre Stadt Dubai soll ihren Umfang verdreifachen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , Sept. ... Penn. , and OptiMed Specialty Pharmacy of ... partnership to offer a strategic hub service that expedites ... highly sought-after personal spirometer, Spiro PD 2.0, and wellness ... A spirometer is a medical device used to measure ...
(Date:9/12/2017)... LAKES, N.J. , Sept. 12, 2017  Consumer reviews on ... Embrace Hearing as the number one company for hearing aids, ... ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):